CardioPharma, Inc. is focused on the global development of combinatorial cardiovascular products aimed at reducing the morbidity and mortality of the world's number one killer - cardiovascular disease - in a cost-effective manner.
According to the American Heart Association, there are over 81 million cardiovascular patients in the US alone suffering from disorders that cause approximately one-third of all US deaths. Further, these disorders cost the US healthcare system over $500 billion each year.1 Internationally, the number of patients and the related healthcare costs are even larger.
Relatedly, many experts believe the number one problem in medicine is patients not taking their medications or not taking them as prescribed, i.e., pharmaceutical non-compliance. Estimates are that as many as 60% of cardiovascular patients do not take their medications as prescribed.2
The CardioPharma pipeline takes aim at these unmet medical needs - in a cost-effective manner - for patients, providers, pharmacists and payers around the world. The pipeline of CardioPharma is dedicated to developing cardiovascular products.
1 - Heart Disease and Stroke Statistics 2010 Update: A Report from the American Heart Association.
2 - Circulation 2010;121:1455-1458